Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome

Chirality

Volumn 23, Issue 2, 2011, Pages 138-143

  Goldberg, Michael E ^a   Torjman, Marc C ^a   Schwartzman, Robert J ^b   Mager, Donald E ^c   Wainer, Irving W ^d  

^a Department of Anesthesiology   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

CRPS; enantioselective; ketamine; liquid chromatography; mass spectrometry; norketamine; pharmacodynamics; pharmacokinetics

Indexed keywords

DRUG METABOLITE; KETAMINE; NORKETAMINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTINOCICEPTION; ARTICLE; CLINICAL ARTICLE; COMPLEX REGIONAL PAIN SYNDROME; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELIMINATION; ENANTIOSELECTIVITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANALGESICS; CHROMATOGRAPHY, LIQUID; COMPLEX REGIONAL PAIN SYNDROMES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MASS SPECTROMETRY; MIDDLE AGED; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650949485     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20890     Document Type: Article

References (30)

1. Schwartzman RJ, Alexander GM, Grothusen J,. Pathophysiology of complex regional pain syndrome. Expert Rev Neurother 2006; 6: 669-681.
2. Veldman PH,., Goris RJ,. Multiple reflex sympathetic dystrophy. Which patients are at risk for developing a recurrence of reflex sympathetic dystrophy in the same or another limb. Pain 1996; 64: 463-466.
3. Maleki J, LeBel AA, Bennett GJ, Schwartzman RJ,. Patterns of spread in complex regional pain syndrome type I (reflex sympathetic dystrophy). Pain 2000; 88: 259-266.
4. Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE,. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med 2004; 5: 263-275.
5. Kvarnstrom A, Karlsten R, Quiding H, Emanuelsson BM, Gordh T,. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand 2003; 47: 868-877.
6. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dahan A,. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain 2009; 145: 304-311.
7. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M,. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 2009; 147: 107-115.
8. Øye I, Paulsen O, Maurset A,. Effects of ketamine on sensory perception: evidence for a role of N-methyl- D -aspartate receptors. J Pharmacol Exp Ther 1992; 260: 1209-1213.
9. White PF, Schuettler J, Shafer A, Stanski DR, Horai Y, Trevor AJ,. Comparative pharmacology of the ketamine isomers. Br J Anaesthesia 1985; 57: 197-203.
10. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM,. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997; 333: 99-104.
11. Rodriguez Rosas ME, Patel S, Wainer IW,. Determination of the enantiomers of ketamine and norketamine in human plasma by enantioselective liquid chromatography-mass spectrometry. J Chromatogr B 2003; 794: 99-108.
12. Mandema JW, Stanski DR,. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60: 619-635.
13. Dayneka NL, Garg V, Jusko WJ,. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-478.
14. Sigtermans M, Dahan A, Mooren R, Bauer M, Kest B, Sarton E, Olofsen E,. S(+)-ketamine effect on experimental pain and cardiac output. Anesthesiology 2009; 111: 892-903.
15. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD,. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using stereoselective analytical method. Br J Anaesthesia 1993; 70: 666-671.
16. Ihmsen H, Geisslinger G, Schuttler J,. Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther 2001; 70: 431-438.
17. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyamo T, Yamamura Y, Yamada Y, Iga T,. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003; 24: 37-43.
18. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, Iga T,. Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001; 29: 887-890.
19. Shimada T, Yamazaki M, Mimura M, Inui Y, Guengerich FP,. Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals-studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
20. Holtman JR, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP,. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 2008; 90: 676-685.
21. Rabben T, Skjelbred P, Øye I,. Prolonged analgesic effect of ketamine, an N-methyl- D -aspartate receptor inhibitor, in patients with chronic pain. Pharmacol Exp Ther 1999; 289: 1060-1066.
22. Adams JD Jr., Baillie TA, Trevor AJ, Castagnoli N, Studies on the biotransformation of ketamine 1-identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed Mass Spectrom 1981; 8: 527-538.
23. Leung LY, Baillie TA,. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 1986; 29: 2396-2399.
24. Kharasch ED, Labroo R,. Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology 1992; 77: 1201-1207.
25. Hijazi Y, Boulieu R,. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30: 853-858.
26. Turfus SC, Parkin MC, Cowan DA, Halket JM, Smith NW, Braithwaite RA, Elliot SP, Steventon GB, Kicman AT,. Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry. Drug Metab Dispos 2009; 37: 1769-1778.
27. Bolze S, and, Boulieu R,. HPLC determination of ketamine, norketamine and dehydronorketamine in plasma with a high-purity reversed-phase sorbent. Clin Chem 1998; 44: 560-564.
28. Williams ML, Mager DE, Parenteau H, Gudi G, Tracy TS, Mulheran M, Wainer IW,. Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab Dispos 2004; 32: 786-793.
29. Wieber J, Gugler R, Hengstmann JH, Dengler HJ,. Pharmacokinetics of ketamine in man. Anaesthesist 1975; 24: 260-263.
30. Trevor AJ, Woolf TF, Baillie TA, Adams JD, Castagnoli,. Stereoselective metabolism of ketamine enantiomers. In:, Kamenka JM, Domino EF, Geneste P, editors. Phencyclidine and Related Arylcyclohexylamines: Present and Future Applications. Ann Arbor, MI: NPP Books; 1983, p 279-289.